52 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

  • Spherix, Inc. SPEX shares surged 66.5% to $2.73 during Monday's pre-market session.
  • Cocrystal Pharma, Inc. COCP stock rose 50.0% to $1.77.
  • Enzo Biochem, Inc. ENZ shares increased by 36.5% to $4.60.
  • China SXT Pharmaceuticals, Inc. SXTC stock increased by 25.6% to $1.08.
  • OPKO Health, Inc. OPK shares rose 24.1% to $2.88.
  • Inovio Pharmaceuticals, Inc. INO shares surged 23.5% to $17.40. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $8.00.
  • Vaxart, Inc. VXRT shares moved upwards by 22.7% to $3.14.
  • Trinity Biotech, Inc. TRIB stock surged 14.3% to $1.60.
  • Kala Pharmaceuticals, Inc. KALA shares increased by 12.3% to $7.05. According to the most recent rating by Bank of America, on December 17, the current rating is at Neutral.
  • Ritter Pharmaceuticals, Inc. RTTR shares surged 8.4% to $0.44.
  • Co-Diagnostics, Inc. CODX stock moved upwards by 8.0% to $13.92. According to the most recent rating by Maxim Group, on March 03, the current rating is at Hold.
  • T2 Biosystems, Inc. TTOO shares moved upwards by 7.6% to $0.60.
  • Spectrum Pharmaceuticals, Inc. SPPI stock surged 7.2% to $2.99. The most recent rating by B. Riley FBR, on March 02, is at Buy, with a price target of $8.00.
  • Tonix Pharmaceuticals, Inc. TNXP shares moved upwards by 6.8% to $1.10.
  • Compugen, Inc. CGEN stock rose 6.3% to $9.95. The most recent rating by Cantor Fitzgerald, on February 21, is at Overweight, with a price target of $13.00.
  • Novavax, Inc. NVAX shares rose 5.8% to $13.20. The most recent rating by B. Riley FBR, on February 28, is at Buy, with a price target of $16.00.

 

Losers

  • NewLink Genetics, Inc. NLNK stock fell 19.6% to $1.11 during Monday's pre-market session.
  • Clovis Oncology, Inc. CLVS stock fell 16.5% to $6.56. The most recent rating by B of A Securities, on January 23, is at Neutral, with a price target of $10.00.
  • Tilray, Inc. TLRY stock decreased by 15.7% to $8.45. According to the most recent rating by Eight Capital, on March 03, the current rating is at Neutral.
  • Canopy Growth, Inc. CGC stock plummeted 14.7% to $13.03. The most recent rating by Stifel Nicolaus, on February 18, is at Buy, with a price target of $35.00.
  • Tocagen, Inc. TOCA stock decreased by 13.2% to $2.50.
  • Bionano Genomics, Inc. BNGO shares declined 12.4% to $0.67.
  • Aurora Cannabis, Inc. ACB stock declined 11.1% to $1.04. The most recent rating by Needham, on February 25, is at Hold, with a price target of $1.50.
  • Amarin Corp, Inc. AMRN shares decreased by 8.7% to $13.62. The most recent rating by Cowen & Co., on March 02, is at Outperform, with a price target of $23.00.
  • Titan Pharmaceuticals, Inc. TTNP stock fell 8.5% to $0.28.
  • Teva Pharmaceutical Indus, Inc. TEVA shares decreased by 8.4% to $9.43. The most recent rating by Wells Fargo, on March 05, is at Equal-Weight, with a price target of $12.00.
  • Verastem, Inc. VSTM shares fell 8.3% to $3.10. The most recent rating by Cantor Fitzgerald, on March 03, is at Overweight, with a price target of $6.00.
  • Enlivex Therapeutics, Inc. ENLV stock plummeted 7.8% to $5.30. The most recent rating by H.C. Wainwright, on January 09, is at Buy, with a price target of $20.00.
  • Aphria, Inc. APHA shares decreased by 7.5% to $2.91. According to the most recent rating by CiBC, on January 15, the current rating is at Neutral.
  • Sorrento Therapeutics, Inc. SRNE shares plummeted 7.2% to $2.05.
  • AbbVie, Inc. ABBV stock declined 7.1% to $82.65. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $97.00.
  • Arrowhead Pharmaceuticals, Inc. ARWR shares declined 7.0% to $31.06. The most recent rating by Cantor Fitzgerald, on February 06, is at Neutral, with a price target of $55.00.
  • Bristol-Myers Squibb, Inc. BMY stock plummeted 6.3% to $56.50. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $69.00.
  • Trillium Therapeutics, Inc. TRIL shares plummeted 6.1% to $6.78.
  • CVS Health, Inc. CVS stock plummeted 6.1% to $60.25. The most recent rating by Deutsche Bank, on February 18, is at Buy, with a price target of $109.00.
  • UnitedHealth Group, Inc. UNH shares decreased by 6.0% to $267.00. The most recent rating by Deutsche Bank, on February 18, is at Hold, with a price target of $362.00.
  • Allied Healthcare Prods, Inc. AHPI stock declined 6.0% to $17.01.
  • Abbott Laboratories, Inc. ABT shares decreased by 5.9% to $76.95. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $94.00.
  • Editas Medicine, Inc. EDIT stock declined 5.8% to $22.57. The most recent rating by Raymond James, on February 27, is at Outperform, with a price target of $41.00.
  • Advaxis, Inc. ADXS stock declined 5.8% to $0.75.
  • ADMA Biologics, Inc. ADMA stock plummeted 5.7% to $2.82.
  • Merck & Co, Inc. MRK shares decreased by 5.5% to $77.70. The most recent rating by UBS, on February 06, is at Buy, with a price target of $96.00.
  • Beyond Air, Inc. XAIR stock plummeted 5.5% to $7.00.
  • Sanofi, Inc. SNY stock declined 5.3% to $45.89. The most recent rating by Argus Research, on February 19, is at Buy, with a price target of $56.00.
  • Royal Philips, Inc. PHG stock plummeted 5.2% to $39.88. The most recent rating by Bank of America, on January 13, is at Buy, with a price target of $51.00.
  • Digirad, Inc. DRAD shares fell 5.0% to $6.50.
  • Pfizer, Inc. PFE shares fell 4.6% to $33.41. The most recent rating by Barclays, on February 27, is at Equal-Weight, with a price target of $36.00.
  • Novo Nordisk, Inc. NVO stock plummeted 4.3% to $59.87. The most recent rating by KeyBanc, on February 19, is at Overweight, with a price target of $18.00.
  • Johnson & Johnson, Inc. JNJ stock plummeted 4.2% to $136.20. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $159.00.
  • Medtronic, Inc. MDT stock fell 4.1% to $94.99. The most recent rating by Credit Suisse, on March 06, is at Outperform, with a price target of $121.00.
  • KemPharm, Inc. KMPH stock decreased by 3.6% to $0.27.
  • Grifols, Inc. GRFS stock fell 3.3% to $21.34.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Pre-Market OutlookMarketsMoversTrading IdeasHealthcare Stocks Pre-Market MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!